The Survey Research and Data Acquisition Resource (SRDAR) is a new CCSG Resource that originated out of the Cancer Prevention and Population Sciences Program in the summer of 2004. The mission of SRDAR is to provide a collaborative Resource within RPCI for data collection and study design services for investigators from CCSG Programs. Collecting valid and reliable survey data is critical for all investigators. SRDAR data collection services include phone surveys, face-to-face interviews, clinical followup assessments, trial recruitment, web-based surveys, mail-based biologic data collection, scannable forms and focus groups. SRDAR can also provide assistance with protocol development and dissemination of findings. The personnel structure includes the Resource Director, scientific coordinator, administrative coordinator, informatics coordinator and data collection staff (currently 30 FTE). Leading up to the designation as a CCSG Resource, RPCI contributed $167,520 in personnel and equipment expenses to create the SRDAR infrastructure. CCSG support will be used to defray these management expenses and chargebacks will cover 66% of the expected $1.1 million FY 2008 operating budget. Since its inception, SRDAR has supported 41 projects and generated $1.1 million in revenue;51% has come from peerreviewed sources, including 40% from NIH grants. As a CCSG Resource, SRDAR will seek to expand its role in research in all CCSG Programs. The Resource is used by two Programs and 88% of users are CCSG members. $98,966 in CCSG support is requested, representing 9% of the total operating budget.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016056-34
Application #
8078045
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2010-05-01
Budget End
2011-04-30
Support Year
34
Fiscal Year
2010
Total Cost
$246,533
Indirect Cost
Name
Roswell Park Cancer Institute Corp
Department
Type
DUNS #
824771034
City
Buffalo
State
NY
Country
United States
Zip Code
14263
Eng, Diana G; Kaverina, Natalya V; Schneider, Remington R S et al. (2018) Detection of renin lineage cell transdifferentiation to podocytes in the kidney glomerulus with dual lineage tracing. Kidney Int 93:1240-1246
Ling, Xiang; Wu, Wenjie; Fan, Chuandong et al. (2018) An ABCG2 non-substrate anticancer agent FL118 targets drug-resistant cancer stem-like cells and overcomes treatment resistance of human pancreatic cancer. J Exp Clin Cancer Res 37:240
Chung, Sejin; Vail, Paris J; Witkiewicz, Agnieszka K et al. (2018) Coordinately targeting cell cycle checkpoint functions in integrated models of pancreatic cancer. Clin Cancer Res :
Mohammadpour, Hemn; O'Neil, Rachel; Qiu, Jingxin et al. (2018) Blockade of Host ?2-Adrenergic Receptor Enhances Graft-versus-Tumor Effect through Modulating APCs. J Immunol 200:2479-2488
Hsu, Alice H; Lum, Michelle A; Shim, Kang-Sup et al. (2018) Crosstalk between PKC? and PI3K/AKT Signaling Is Tumor Suppressive in the Endometrium. Cell Rep 24:655-669
Sandlesh, Poorva; Juang, Thierry; Safina, Alfiya et al. (2018) Uncovering the fine print of the CreERT2-LoxP system while generating a conditional knockout mouse model of Ssrp1 gene. PLoS One 13:e0199785
Zhang, Dingxiao; Zhao, Shuhong; Li, Xinyun et al. (2018) Prostate Luminal Progenitor Cells in Development and Cancer. Trends Cancer 4:769-783
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330
Damayanti, Nur P; Budka, Justin A; Khella, Heba W Z et al. (2018) Therapeutic Targeting of TFE3/IRS-1/PI3K/mTOR Axis in Translocation Renal Cell Carcinoma. Clin Cancer Res 24:5977-5989
Mayor, Paul; Starbuck, Kristen; Zsiros, Emese (2018) Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies. Gynecol Oncol 150:361-369

Showing the most recent 10 out of 1555 publications